Business Description
Zim Laboratories Ltd
ISIN : INE518E01015
Share Class Description:
NSE:ZIMLAB: Ordinary SharesTotal Employee Number:
632Compare
Compare
Traded in other countries / regions
541400.India IPO Date
2022-11-25Description
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.22 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.43 | |||||
Debt-to-EBITDA | 3.05 | |||||
Interest Coverage | 0.76 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.05 | |||||
Beneish M-Score | -2.8 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.7 | |||||
3-Year EBITDA Growth Rate | -11.5 | |||||
3-Year EPS without NRI Growth Rate | -43.1 | |||||
3-Year FCF Growth Rate | 50.6 | |||||
3-Year Book Growth Rate | 10.4 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.63 | |||||
9-Day RSI | 67.54 | |||||
14-Day RSI | 67.99 | |||||
3-1 Month Momentum % | 56.66 | |||||
6-1 Month Momentum % | 41.82 | |||||
12-1 Month Momentum % | -9.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.45 | |||||
Quick Ratio | 0.96 | |||||
Cash Ratio | 0.15 | |||||
Days Inventory | 202.93 | |||||
Days Sales Outstanding | 103.35 | |||||
Days Payable | 150.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.2 | |||||
Shareholder Yield % | -7.79 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 55.83 | |||||
Operating Margin % | 2.68 | |||||
Net Margin % | 1.56 | |||||
EBITDA Margin % | 11.06 | |||||
FCF Margin % | 1.37 | |||||
OCF Margin % | 13.23 | |||||
ROE % | 2.19 | |||||
ROA % | 1.18 | |||||
ROIC % | 1.74 | |||||
3-Year ROIIC % | -10.3 | |||||
ROC (Joel Greenblatt) % | 6.23 | |||||
ROCE % | 6.66 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 104.98 | |||||
PE Ratio without NRI | 104.98 | |||||
Shiller PE Ratio | 33.44 | |||||
Price-to-Owner-Earnings | 89.41 | |||||
PEG Ratio | 58.32 | |||||
PS Ratio | 1.62 | |||||
PB Ratio | 2.26 | |||||
Price-to-Tangible-Book | 2.63 | |||||
Price-to-Free-Cash-Flow | 118.85 | |||||
Price-to-Operating-Cash-Flow | 12.35 | |||||
EV-to-EBIT | 35.57 | |||||
EV-to-EBITDA | 18.4 | |||||
EV-to-Revenue | 2.04 | |||||
EV-to-FCF | 143.41 | |||||
Price-to-GF-Value | 1.21 | |||||
Price-to-Projected-FCF | 2.39 | |||||
Price-to-DCF (Earnings Based) | 11.3 | |||||
Price-to-DCF (FCF Based) | 4.99 | |||||
Price-to-Graham-Number | 3.5 | |||||
| Price-to-Net-Current-Asset-Value | 20.51 | |||||
Earnings Yield (Greenblatt) % | 2.8 | |||||
FCF Yield % | 0.76 | |||||
Forward Rate of Return (Yacktman) % | 2.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zim Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 3,744.001 | ||
| EPS (TTM) (₹) | 1.19 | ||
| Beta | 1.5368 | ||
| 3-Year Sharpe Ratio | 0.11 | ||
| 3-Year Sortino Ratio | 0.2 | ||
| Volatility % | 67.02 | ||
| 14-Day RSI | 67.99 | ||
| 14-Day ATR (₹) | 7.169797 | ||
| 20-Day SMA (₹) | 112.633 | ||
| 12-1 Month Momentum % | -9.92 | ||
| 52-Week Range (₹) | 59.31 - 133.9 | ||
| Shares Outstanding (Mil) | 53.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zim Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zim Laboratories Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| 3:1 Stock Split | 2022-12-22 | 110.60 (-2.58%) |
Show
Entries
Zim Laboratories Ltd Frequently Asked Questions
What is Zim Laboratories Ltd(NSE:ZIMLAB)'s stock price today?
The current price of NSE:ZIMLAB is ₹124.90. The 52 week high of NSE:ZIMLAB is ₹133.90 and 52 week low is ₹59.31.
When is next earnings date of Zim Laboratories Ltd(NSE:ZIMLAB)?
The next earnings date of Zim Laboratories Ltd(NSE:ZIMLAB) is .
Does Zim Laboratories Ltd(NSE:ZIMLAB) pay dividends? If so, how much?
Zim Laboratories Ltd(NSE:ZIMLAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Zim Laboratories Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers